A Phase 2 interventional study of Q fever Vaccine in Q Fever, sponsored by U.S. Army Medical Research and Development Command. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-02.
Sponsored by U.S. Army Medical Research and Development Command · Phase 2, Interventional, and Prevention
The purpose of this study is to evaluate the safety of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 and collect data on incidence of occupational Q fever infection in vaccinated personnel.
U.S. Army Medical Research and Development Command is the lead sponsor of 153 studies on the registry; 8 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 16 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have on their charts:
Exclusion Criteria:
Any known allergies to components of the vaccine:
The vaccine will be administered subcutaneously in the upper outer aspect of the arm (triceps area) with 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 (which equals 30 μg)
Biological: Q fever Vaccine
Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
Also known as: Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
Change in Immunogenicity
Immune response will be evaluated for per protocol subjects to determine the percentage of subjects who experience a ≥ fourfold rise in immunofluorescence assay (IFA) antibody titer after vaccination. Immunoglobulin M (IgM) at Day 28 or Day 56, or immunoglobulin G (IgG) at 6 months.
Time frame: Day 28, Day 56, or 6 months
Percentage of subjects with symptoms following Q fever vaccination
Time frame: 6 months
Percentage of subjects with erythema following Q fever vaccination along with severity and association with vaccination
Time frame: 6 months
Percentage of subjects with induration following Q fever vaccination along with severity and association with vaccination
Time frame: 6 months
Percentage of subjects with each AE, system organ class of AE, severity, and association with vaccination
Time frame: 6 months
Percentage of subjects with symptoms following Q fever skin test antigen
Time frame: 6 months
Percentage of subjects with erythema following Q fever skin test antigen along with severity and association with skin test antigen
Time frame: 6 months
Percentage of subjects with induration following Q fever skin test antigen along with severity and association with skin test antigen
Time frame: 6 months
Percentage of subjects with each AE, system organ class of AE, severity, and association with skin test antigen
Time frame: 6 months
The record gives a start of Feb 2006, a primary completion of Feb 2019 and a completion of Dec 2019. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Q Fever
U.S. Army Medical Research and Development Command →